Validated Measure Assesses the Impact of Treatment for Growth Hormone Deficiency in Children – AJMC.com Managed Markets Network

A validation of the observer-reported outcome of the Growth Hormone Deficiency-Child Impact Measure found it valid and reliable to understand the impact of treatment with growth hormone therapy. A psychometric validation of the observer-reported outcome (ObsRO) of the Growth Hormone Deficiency-Child Impact Measure (GHD-CIM) found it is a valid and reliable measure that can provide a patient-centric picture to the experience children have with growth hormone therapy, according to a study published in PharmacoEconomics Open.

Novel App Could Help Earlier Detection of Growth Disorders – Medscape

A smartphone application that allows parents and carers to measure and monitor their childs height accurately could be used to help in the earlier detection of growth disorders, according to the results of a pilot study. The GrowthMonitor smartphone app was developed by UK researchers to help tackle delays in the diagnosis of growth disorders, which they say are common in the UK. Unlike in other European countries, child growth monitoring has not been a priority and potentially treatable problems are often diagnosed late.

Global Biosimilars and Follow-on Biologics R&D Market is projected to reach a market value of US$ 2,22,576.5 Million in 2031: Visiongain Research Inc…

Visiongain has launched a new report Biosimilars and Follow-On Biologics Market Report 2021-2031: Forecasts by Type of Manufacturing (In-House, CMOs), by Type (Monoclonal Antibodies, Fusion Proteins, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Interferon, Growth Hormones, Fertility Hormones, Others), by Application (Blood Disorders, Oncology Diseases, Chronic & Autoimmune Diseases, Growth Hormone Deficiencies, Others), by Technology (rDNA Technology, mAb Technology, Bioassay Technology) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios. Download Exclusive Sample of Report @ https://www.visiongain.com/report/biosimilars-market-2021/#download_sampe_div Global Biosimilars and Follow-on Biologics R&D Market Outlook According to Visiongain analysis, Global Biosimilars and Follow-on biologics R&D market was valued at US$12,250.0 million in 2020

Biosimilars Market by Product, Indication and Region – Global Forecast to 2026 – PRNewswire

DUBLIN, Nov. 10, 2021 /PRNewswire/ -- The "Global Biosimilars Market by Product (Monoclonal antibodies (infliximab, rituximab, trastuzumab), Insulin, Interferon, Etanercept, Glucagon, Calcitonin), Indication (Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease), Region - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering. The global biosimilars market is projected to reach USD 44.7 billion by 2026 from USD 15.6 billion in 2021, at a CAGR of 23.5% during the forecast period of 2021 to 2026

Dong-A ST’s sales of prescription drugs up 24% in Q3 – Korea Biomedical Review

Dong-A STs sales and operating profit increased thanks to the growth of prescription drugs in the third quarter, the company said. As the company improved profitability even before receiving fees for licensing out a Stelara biosimilar to Indias Intas Pharmaceuticals, the companys earnings are expected to grow more, analysts said. Dong-A ST said in a public filing that its third-quarter revenue increased 4.3 percent on-year to 151.9 billion won ($128.9 million).